Research programme: infectious disease therapeutics - Synthetic Biologics/Intrexon Corporation

Drug Profile

Research programme: infectious disease therapeutics - Synthetic Biologics/Intrexon Corporation

Alternative Names: anti-Acinetobacter mAbs - Synthetic Biologics/Intrexon; anti-pertussis mAbs - Synthetic Biologics/Intrexon; hu1B7; Pertussis (whooping cough) monoclonal antibody - Synthetic Biologics; SYN-001; SYN-005; SYN-007

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Intrexon Corporation; Synthetic Biologics
  • Developer Intrexon Corporation; Synthetic Biologics; University of Texas at Austin
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pertussis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pertussis; Phenylketonuria
  • Research Inflammatory bowel diseases
  • No development reported Acinetobacter infections; Infections

Most Recent Events

  • 13 Dec 2016 Synthetic Biologics receives patent allowance for SYN 005 in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Acinetobacter-infections in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top